EHA 2020

Myeloid

VIALE-A: newly diagnosed chemo-ineligible AML

Presented By

Dr Courtney Di Nardo, MD Anderson Cancer Centre, USA

Trial

Phase 3, VIALE-A

Conference

EHA 2020

9 September, 2020 13:25

OS benefit in VIALE-C trial

Presented By

Prof. Andrew Wei, Monash University, Australia

Trial

Phase 3, VIALE-C

Conference

EHA 2020

9 September, 2020 13:22

DEC10-VEN superior to intensive chemotherapy in high-risk AML

Presented By

Dr Abhishek Maiti, University of Texas MD Anderson Cancer Centre, USA

Trial

Phase 2

Conference

EHA 2020

9 September, 2020 13:18

Magrolimab plus azacitidine: good ORR in MDS/AML

Presented By

Prof. Naval Draver, University of Texas MD Anderson Cancer Centre, USA

Trial

Phase 1

Conference

EHA 2020

9 September, 2020 13:14

Asciminib monotherapy in Ph+ CML: major molecular responses

Presented By

Prof. Timothy Hughes, University of Adelaide, Australia

Trial

Phase 1

Conference

EHA 2020

9 September, 2020 13:08

CML TKI interruption: Swedish registry results

Presented By

Dr Hjalmar Flygt, Uppsala University Hospital, Sweden

Conference

EHA 2020

9 September, 2020 13:03

Patients with lower-risk MDS benefit from imetelstat

Presented By

Prof. Uwe Platzbecker, University Clinic Leipzig, Germany

Trial

Phase 2, IMerge

Conference

EHA 2020

9 September, 2020 12:59

Better outcomes adding enasidenib to azacitidine in mIDH2-AML

Presented By

Dr Courtney Di Nardo, MD Anderson Cancer Centre, USA

Trial

Phase 2, AG-221-AML-005

Conference

EHA 2020

9 September, 2020 12:55

Lymphoid

PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma

Presented By

Dr Peter Borchmann, University Hospital of Cologne, Germany

Trial

Phase 3, HD17

Conference

EHA 2020

9 September, 2020 12:51

Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma

Presented By

Prof. Pier Luigi Zinzani, University of Bologna, Italy

Trial

Phase 3, KEYNOTE-204

Conference

EHA 2020

9 September, 2020 12:38

Promising first-in-human trial of epcoritamab in B-NHL

Presented By

Dr Martin Hutchings, Copenhagen University Hospital, Denmark

Trial

Phase 1/2, GEN3013

Conference

EHA 2020

9 September, 2020 12:30

Two trials: acalabrutinib in CLL

Presented By

Prof. John Byrd, Ohio State University Comprehensive Cancer Centre, USA

Trial

Phase 2, ACE-CL-001, ASCEND

Conference

EHA 2020

9 September, 2020 12:19

Zanubrutinib versus ibrutinib in Waldenström macroglobulinaemia

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, ASPEN

Conference

EHA 2020

9 September, 2020 12:10

Deep responses in R/R CLL with venetoclax monotherapy

Expert

Prof. Arnon Kater, Amsterdam University Medical Center, the Netherlands

Trial

Phase 3, VENICE 1

Conference

EHA 2020

9 September, 2020 11:35

MRD assessment post-CAR-T predicts ALL allo-HSCT bridging

Expert

Dr Hui Wang, Hebei Yanda Ludaopei Hospital, China

Conference

EHA 2020

9 September, 2020 11:02

Plasma Cell Dyscrasias

Daratumumab for light-chain amyloidosis

Presented By

Dr Efstathios Kastritis, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, ANDROMEDA

Conference

EHA 2020

9 September, 2020 10:49

Isatuximab triplet improves PFS in R/R MM

Presented By

Prof. Philippe Moreau, University Hospital of Nantes, France

Trial

Phase 3, IKEMA

Conference

EHA 2020

9 September, 2020 10:26

Initial results from CAR-T cell therapy in MM: KarMMa

Presented By

Prof. Jesús San Miguel, University of Navarra, Spain

Conference

EHA 2020

9 September, 2020 10:19

Graft-Versus-Host Disease

Benign Haematology

Paediatric Haematology

Venetoclax + navitoclax promising for R/R ALL or LL

Presented By

Prof. Elias Jabbour , University of Texas MS Anderson Cancer Centre, USA

Trial

Phase 1

Conference

EHA 2020

28 August, 2020 12:23

Nivolumab/brentuximab vedotin in R/R HL: good CMR rates

Presented By

Prof. Christine Mauz-Körholz, Justus-Liebig-Universität Gießen, Germany

Trial

Phase 2, Checkmate 744

Conference

EHA 2020

28 August, 2020 12:09

Bench-to-Bedside Science from the Presidential Symposium